Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (141-150 of 166) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Blood Advances|August 21, 2023
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology studyBhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2012
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsFariba Navid, Sharyn D Baker, M Beth McCarville, et al.
Molecular Cancer Therapeutics|September 14, 2021
Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD-Positive AMLMegan E Zavorka Thomas, Xiyuan Lu, Zahra Talebi, et al.
Clinical and Translational Science|July 28, 2019
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AMLDaelynn R Buelow, Stanley B Pounds, Yong-Dong Wang, et al.
Research Square|July 3, 2023
Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosisMasayuki Umeda, Jing Ma, Tamara Westover, et al.
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Pageof 17

Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis, Elisabeth I Heath, Janet R Walczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patientsErin R Lepper, Sharyn D Baker, Matt Permenter, et al.
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.
Blood Advances|August 21, 2023
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology studyBhavana Bhatnagar, Jessica Kohlschmidt, Shelley J Orwick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2012
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsFariba Navid, Sharyn D Baker, M Beth McCarville, et al.
Molecular Cancer Therapeutics|September 14, 2021
Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i>-ITD-Positive AMLMegan E Zavorka Thomas, Xiyuan Lu, Zahra Talebi, et al.
Clinical and Translational Science|July 28, 2019
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AMLDaelynn R Buelow, Stanley B Pounds, Yong-Dong Wang, et al.
Research Square|July 3, 2023
Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosisMasayuki Umeda, Jing Ma, Tamara Westover, et al.
Leukemia|January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studiesNadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Pageof 17